Stocks · News reference

Reported Earlier, Silence Therapeutics Prices Upsized $175M Underwritten Public Offering Of 12,962,963 ADSs At $13.50 Per ADS

Aug 12, 2026, 6:58 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 11, 2026, 3:52 PMBenzinga Newsdesk
Morgan Stanley Maintains Overweight on Silence Therapeutics, Raises Price Target to $32
Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and raises the price target from $25 to $32.
Read original at benzinga
SLN
BenzingaAug 10, 2026, 8:04 PMBenzinga Newsdesk
Silence Therapeutics Announces Commencement Of Approximately $150M Underwritten Public Offering Of American Depositary Shares
Read original at benzinga
SLN
BenzingaAug 10, 2026, 2:15 PMVandana Singh
Silence Therapeutics Says Blood Cancer Trial Delivers 'Best-Case Outcome'
Silence Therapeutics reports positive Phase 2 SANRECO trial data for divesiran in polycythemia vera. Phase 3 trial planned for 1H 2027.
Read original at benzinga
SLN